- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT07947043
Exploratory Clinical Study of Autologous Tumor-Infiltrating Lymphocytes (TIL) Injection
An Exploratory Clinical Study on the Safety, Tolerability, and Preliminary Efficacy of Autologous Tumor-Infiltrating Lymphocyte (TIL) Infusion for the Treatment of Recurrent/Metastatic Lung Cancer or Cervical Cancer in Previously Treated Patients.
This study is a single - center, single - arm, open - label, single - dose, dose - escalation exploratory study. The main purpose is to evaluate the safety and tolerability of autologous tumor - infiltrating lymphocyte injection in the treatment of recurrent or metastatic lung cancer or cervical cancer. Meanwhile, it will also preliminarily explore the effectiveness, PK characteristics, PD characteristics and changes in immune - related parameters of autologous tumor - infiltrating lymphocyte injection in subjects with recurrent or metastatic lung cancer or cervical cancer.
Přehled studie
Postavení
Intervence / Léčba
Typ studie
Zápis (Odhadovaný)
Fáze
- Fáze 1
Kontakty a umístění
Studijní místa
-
-
Hubei
-
Wuhan, Hubei, Čína, 430030
- Nábor
- Tongji Hospital
-
Kontakt:
- Qian Chu
- Telefonní číslo: 02783662379
- E-mail: qianchu@tjh.tjmu.edu.cn
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- 1.The patient voluntarily signs the informed consent form and is able to complete the study procedures, follow-up examinations and treatments.
- 2.Aged 18 to 75 years old, regardless of gender.
- 3.Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1.
- 4.Patients with pathologically confirmed recurrent or metastatic malignant lung cancer or cervical cancer (confirmed by cytology or histopathology) who have failed or are intolerant to standard treatment, or have no standard treatment plan.
- 5.The subject has at least one eligible tumor lesion/tissue for TIL preparation.
- 6.After TIL sampling and excisional biopsy, the subject must have at least one measurable tumor lesion in accordance with the RECIST 1.1 criteria.
- 7.Expected survival time > 6 months.
- 8.Sufficient hematological and end-organ function as defined by the following laboratory test results, which must be completed within 7 days before TIL tumor tissue collection: Routine blood test: White blood cell count ≥ 2.5×10⁹/L; Absolute neutrophil count (ANC) ≥ 1.5×10⁹/L; Absolute lymphocyte count (ALC) ≥ 0.7×10⁹/L; Platelet (PLT) ≥ 100×10⁹/L; Hemoglobin (HGB) ≥ 90g/L; Coagulation function: International normalized ratio (INR) ≤ 1.5×ULN, unless anticoagulant therapy was received within the previous 7 days; Activated partial thromboplastin time (APTT) ≤ 1.5×ULN, unless anticoagulant therapy was received within the previous 7 days; Renal function: Serum creatinine ≤ 1.5mg/dL (or 132.6μmol/L) or creatinine clearance ≥ 60mL/min; Urine protein < 2+ in routine urine test, or 24-hour urine protein quantification < 1g; Liver function: Aspartate aminotransferase (AST/SGOT) ≤ 3×ULN; Alanine aminotransferase (ALT/SGPT) ≤ 3×ULN; Total bilirubin (TBIL) ≤ 1.5×ULN. Note: For patients with liver metastasis or primary liver tumor lesions, AST and ALT must be ≤ 5×ULN; For patients with a history of Gilbert's syndrome or suspected of having the disease, TBIL must be ≤ 3×ULN.
- 9.Toxic reactions caused by previous treatment (excluding disease-related ones) have recovered to ≤ Grade 1 before enrollment (excluding alopecia and ≤ Grade 2 neurotoxicity caused by chemotherapy drugs).
- 10.Women of childbearing age must have a negative serum pregnancy test within 7 days before enrollment. Any male or female patient of childbearing potential must agree to use effective contraceptive methods from enrollment until at least 6 months after TIL cell infusion. A patient is considered to have childbearing potential as judged by the investigator if he/she is biologically capable of having children and has normal sexual activity. Female patients without childbearing potential must meet at least one of the following criteria: Has undergone hysterectomy or bilateral oophorectomy; Medically confirmed ovarian failure; Medically confirmed postmenopause (at least 12 consecutive months of amenorrhea).
- 11.Able to comply with the study protocol as judged by the investigator.
Exclusion Criteria:
- 1.Patients with only bone metastatic lesions or central nervous system metastatic lesions.
- 2.Patients who have previously received any adoptive cell therapy.
- 3.Patients who have received any systemic anti-tumor treatment (including chemotherapy, radiotherapy, molecular targeted therapy, etc.) within 4 weeks before preconditioning.
- 4.Patients who have received systemic corticosteroid therapy for immunosuppression (≥10mg/day, excluding inhaled therapy, local therapy or physiological replacement therapy) or other immunosuppressive drug therapy within 2 weeks before preconditioning.
- 5.Patients who have undergone major surgery deemed unsuitable for enrollment by the investigator within 4 weeks before screening, or plan to undergo other major surgeries (excluding the planned surgery for TIL cell preparation as specified in the protocol) during the study period.
- 6.Patients with other malignant tumors within 5 years before screening or at the same time (excluding patients with locally treated malignant tumors who do not require treatment for more than 1 year and have no significant recurrence risk as judged by the investigator).
- 7.Patients with active or suspected autoimmune or inflammatory diseases (including but not limited to rheumatoid arthritis, autoimmune thyroiditis, autoimmune hepatitis, autoimmune hemolytic anemia, scleroderma, systemic lupus erythematosus, Wegener's granulomatosis, ulcerative colitis, Crohn's disease, etc.).
- 8.Patients with a history of organ transplantation or hematopoietic stem cell transplantation.
- 9.Patients with any of the following infections: Hepatitis B (positive for hepatitis B surface antigen [HbsAg] and/or hepatitis B core antibody [HbcAb]; patients with HBVDNA < 1000 copies/ml are eligible for enrollment); Hepatitis C (positive for HCV antibody test and positive for HCV-RNA test); Patients with systemic active infections requiring antibiotic treatment (e.g., sepsis, acteremia, fungemia, etc.); Patients with congenital or acquired immunodeficiency (including but not limited to severe combined immunodeficiency disease, patients with HIV infection, etc.); Patients positive for TP antibody or HTLV-1 antibody.
- 10.Patients who have received live vaccines or attenuated vaccines within 4 weeks before preconditioning.
- 11.Patients with symptomatic and/or untreated brain metastases (patients whose symptoms are stable for ≥14 days after clear treatment before preconditioning may be considered for enrollment).
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: N/A
- Intervenční model: Přiřazení jedné skupiny
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: Autologous Tumor-Infiltrating Lymphocyte Injection
Autologous Tumor-Infiltrating Lymphocyte Injection with a single administration dose of 1×10¹⁰ (±20%), 3×10¹⁰ (±20%), and 5×10¹⁰ (±20%) cells per person per administration respectively. |
DK008 |
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
ORR
Časové okno: Up to 12 months after first dose
|
Objective Response Rate (ORR) is defined as the proportion of patients who achieve a complete response (CR) or partial response (PR) to treatment, as assessed by imaging or clinical criteria. Tumor response is typically evaluated using standardized criteria such as the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. |
Up to 12 months after first dose
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
PFS
Časové okno: From date of first study treatment until the date of first documented disease progression or death from any cause, whichever comes first, assessed up to 36 months.
|
Progression-Free Survival (PFS) is defined as the time from the date of randomization (or initiation of treatment) to the date of disease progression or death from any cause, whichever occurs first. Disease progression is assessed according to standardized criteria such as RECIST version 1.1 |
From date of first study treatment until the date of first documented disease progression or death from any cause, whichever comes first, assessed up to 36 months.
|
|
DOR
Časové okno: From date of first study treatment until the date of first documented disease progression or death from any cause, whichever comes first, assessed up to 36 months.
|
Duration of Response (DOR) is defined as the time from the first documented evidence of a complete response (CR) or partial response (PR) until the date of disease progression or death from any cause, whichever occurs first. Tumor responses are assessed based on standardized criteria such as RECIST version 1.1. |
From date of first study treatment until the date of first documented disease progression or death from any cause, whichever comes first, assessed up to 36 months.
|
|
OS
Časové okno: From date of first study treatment until the date of death from any cause, whichever comes first, assessed up to 60 months.
|
Overall Survival (OS) is defined as the time from the date of randomization (or initiation of treatment) to the date of death from any cause. |
From date of first study treatment until the date of death from any cause, whichever comes first, assessed up to 60 months.
|
Další výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
T Cell Subsets Associated with Pharmacokinetics
Časové okno: Within 30min before TIL infusion in day0, and Day1±1 hours, Day2±2 hours, Day4±1 day, Day7±1 day, Day14±1 day,Day21±1 day, Day28±1 day, Day42±3 days post TIL infusion
|
Pharmacokinetic (PK) assessments were conducted to evaluate the absorption, distribution, metabolism, and excretion of the study drug. Immunophenotyping of T cell subsets associated with study drug pharmacokinetics. Measurements include absolute cell counts, relative percentages, and percentage change from baselin. |
Within 30min before TIL infusion in day0, and Day1±1 hours, Day2±2 hours, Day4±1 day, Day7±1 day, Day14±1 day,Day21±1 day, Day28±1 day, Day42±3 days post TIL infusion
|
|
PD-Related T Cell Subsets
Časové okno: Within 30 minutes prior to TIL infusionin Day0, Day14±1 day, Day28±1 day, Day42±3 days,Day84±3 days, Day126±3 days, Day168±3 days after TIL infusion, and at early withdrawal visit.
|
Pharmacodynamic (PD) assessments were performed to evaluate the biological effects and mechanism of action of the study drug. Immunophenotyping of efficacy-associated T cell subsets by flow cytometry. |
Within 30 minutes prior to TIL infusionin Day0, Day14±1 day, Day28±1 day, Day42±3 days,Day84±3 days, Day126±3 days, Day168±3 days after TIL infusion, and at early withdrawal visit.
|
|
ADA
Časové okno: Within 30 minutes prior to TIL infusion in Day0, at Day7±1 day, Day14±1 day, Day28±1 day, and Day42±3 day after TIL infusion.
|
Anti-drug antibody (ADA) assessments were performed to evaluate the immunogenicity of the study drug. |
Within 30 minutes prior to TIL infusion in Day0, at Day7±1 day, Day14±1 day, Day28±1 day, and Day42±3 day after TIL infusion.
|
Spolupracovníci a vyšetřovatelé
Sponzor
Spolupracovníci
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Odhadovaný)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
- Urogenitální onemocnění
- Onemocnění genitálií
- Patologické procesy
- Urogenitální novotvary
- Novotvary podle místa
- Novotvary
- Ženské urogenitální onemocnění
- Ženské urogenitální onemocnění a těhotenské komplikace
- Atributy nemoci
- Nemoci dýchacích cest
- Onemocnění dělohy
- Onemocnění pohlavních orgánů, ženy
- Plicní onemocnění
- Novotvary dýchacího traktu
- Novotvary hrudníku
- Genitální novotvary, ženy
- Onemocnění děložního čípku
- Novotvary dělohy
- Patologické stavy, příznaky a symptomy
- Opakování
- Novotvary plic
- Novotvary děložního čípku
Další identifikační čísla studie
- KFP-2024-DK008-003
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .